Haixia He

机构：Guangzhou University of Chinese Medicine, Southwestern Medical Center, First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Multimeric Biotherapeutics (United States), The University of Texas Southwestern Medical Center · ORCID：0000-0002-9237-3474

发表论文 79 篇 · 总被引 1581 次 · h-index 20

代表论文

• EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors (2023 · Science Advances · 被引 89)
• Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study (2024 · Signal Transduction and Targeted Therapy · 被引 36)
• MT1G , an emerging ferroptosis‐related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer (2023 · Environmental Toxicology · 被引 20)
• PTBP1 Regulates DNMT3B Alternative Splicing by Interacting With RALY to Enhance the Radioresistance of Prostate Cancer (2024 · Advanced Science · 被引 18)
• Assessment of treatment outcomes: cytoreductive surgery compared to radiotherapy in oligometastatic prostate cancer – an in-depth quantitative evaluation and retrospective cohort analysis (2024 · International Journal of Surgery · 被引 12)
• Water and chloride as allosteric inhibitors in WNK kinase osmosensing (2023 · eLife · 被引 7)